Cogent Biosciences

Cogent Biosciences is a biotechnology company that develops precision therapeutics to treat patients with unmet medical needs. The lead program, bezuclastinib, is a selective KIT inhibitor that is being tested in clinical trials for Systemic Mastocytosis and Gastrointestinal Stromal Tumor.